The findings point to a "real need for better tools to identify which women may benefit from screening and which breast cancers are unlikely to be progressive." 

The technology was able to detect about 20% more cancers when compared to standard screening, without impacting false positives.

Paris, France-based Sonio also recently raised $14 million in series A financing led by Cross Border Impact Ventures. 

What’s more, the model proved beneficial in a large, diverse cohort that included women with benign breast disease and BRCA mutations.

Breast radiologists are known to have higher rates of burnout in comparison to many of their peers, but the beginning of the pandemic brought this group something not often encountered within the specialty—downtime. 

"This system is bringing with it a greater humanization of AI and therefore a more realistic representation of what we do as radiologists,” one member of the specialty said. 

ICAD Inc. said the deal spans multiple years and will see the nation’s largest radiology group adopting its breast  technology across the enterprise.

Scientists see important implications from their work as practice leaders seek to improve efficiency and the patient experience.